Cramer's 'Mad Money' Recap: Looking at the Bright Side

Speculation Friday

In this segment, Cramer featured the stock of Sequenom (SQNM Quote), a genetic testing company with potentially tremendous upside.

Sequenom is currently developing a non-invasive test for chromosomal abnormalities such as Downs Syndrome. Cramer said that unlike current invasive tests, like amniocentesis, which carry life threatening risks to the fetus, Sequenom's tests captures fetal cells in the mother's blood and carries no risk to mother or child.

Cramer said the new test could be revolutionary, allowing prospective parents to test for Downs Syndrome in just 12 weeks gestation instead of the current 20 weeks. The new test also doesn't require pre-market FDA approval, making its June 2009 launch date more certain.

Sequenom predicts the market for their new test could potentially reach $1.2 billion a year in the U.S. and as much as $3.5 billion worldwide. Cramer said the company could be a potential takeover target if its trial data continues to be as promising as the 99.1% detection rate the test is current achieving.

Outrage of the Day

Cramer again took aim at SEC Chairman Chris Cox, who today held a press conference and in an incredible act of selfishness and disloyalty, blamed his entire agency for not discovering Bernie Madoff's alleged fraud sooner.

Cramer called the action "unbelievable" and renamed his "Wall of Shame" list of the worst CEOs to "The Cox-Madoff Memorial Wall of Shame."

In other Wall of Shame news, Cramer removed Citigroup (C Quote) CEO Vikram Pandit from the wall, saying that the government's bailout of the company is the first one that may actually be good for shareholders. He said the value of Citi's huge deposit base can now be leveraged and the true value of the company might be unlocked.